{"gene":"NT5C2","run_date":"2026-04-29T11:37:57","timeline":{"discoveries":[{"year":2013,"finding":"Activating mutations in NT5C2 (cytosolic 5'-nucleotidase II) confer increased nucleotidase activity in vitro and drive resistance to 6-mercaptopurine and 6-thioguanine chemotherapy when expressed in ALL lymphoblasts, identifying NT5C2 as the enzyme responsible for inactivation of nucleoside-analog chemotherapy drugs.","method":"Whole-exome sequencing of relapsed ALL samples, in vitro enzymatic activity assays of mutant proteins, expression of mutant NT5C2 in ALL lymphoblasts with chemotherapy resistance readout","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro enzymatic assay plus functional cell-based resistance assay, independently replicated in concurrent paper (PMID:23377183)","pmids":["23377281"],"is_preprint":false},{"year":2013,"finding":"Relapse-specific NT5C2 base substitution mutations confer increased enzymatic (5'-nucleotidase) activity and resistance to nucleoside analog therapies; all affected individuals harboring NT5C2 mutations relapsed early (within 36 months), consistent with outgrowth of drug-resistant clones.","method":"RNA sequencing of matched diagnosis/relapse bone marrow, full-exon sequencing of NT5C2, enzymatic analysis of mutant proteins showing increased activity","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1-2 — enzymatic characterization of mutant proteins, replicated across independent cohort","pmids":["23377183"],"is_preprint":false},{"year":2018,"finding":"Crystal structures of NT5C2 mutants K359Q and L375F reveal they reconfigure the catalytic center for substrate access and catalysis in the absence of allosteric activator; most relapse-associated mutations in the arm segment and inter-monomeric cavity disrupt a built-in switch-off mechanism; the C-terminal acidic tail (lost in Q523X) functions to restrain NT5C2 activation.","method":"X-ray crystallography of wild-type and mutant NT5C2 proteins, functional enzymatic assays, mutagenesis","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 1 — crystal structures combined with functional mutagenesis and enzymatic assays in a single rigorous study","pmids":["29990496"],"is_preprint":false},{"year":2018,"finding":"All leukemia-associated NT5C2 mutants are constitutively active independent of allosteric ATP effects; 90% of leukemia-specific alleles directly affect two regulatory hotspots (helix A region residues 355-365, and intersubunit interface helix B 232-242 and flexible loop L 400-418); activation is transmitted from mutant to wild-type subunits in hetero-oligomeric complexes, explaining dominant activity from heterozygous mutations.","method":"Structural mapping of mutations, biochemical characterization of hetero-oligomeric complexes combining wild-type and mutant subunits, enzymatic activity assays","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 1-2 — structural mapping plus biochemical reconstitution of hetero-oligomers with functional readout","pmids":["29535428"],"is_preprint":false},{"year":2018,"finding":"Expression of NT5C2 R367Q mutation induces resistance to 6-mercaptopurine at the cost of impaired leukemia cell growth and leukaemia-initiating cell activity due to excess export of purines to the extracellular space and depletion of the intracellular purine-nucleotide pool; inhibition of IMPDH increased cytotoxicity against NT5C2-mutant lymphoblasts.","method":"Conditional-and-inducible leukaemia mouse model expressing NT5C2 R367Q, intracellular purine nucleotide pool measurements, IMPDH inhibition experiments","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — in vivo conditional model with multiple orthogonal mechanistic readouts (nucleotide pool, cell growth, self-renewal, drug sensitivity)","pmids":["29342136"],"is_preprint":false},{"year":2019,"finding":"NT5C2 mutant proteins show elevated 5'-nucleotidase activity with preferential activity toward thiopurine metabolites over endogenous purine nucleotides (neomorphic substrate preference); mutant NT5C2 expression reduces thiopurine uptake and increases efflux of 6-MP metabolites, and causes global shifts in intracellular nucleotide homeostasis.","method":"Biochemical enzymatic assays with mutant vs. wild-type NT5C2, intracellular metabolomic profiling, drug uptake and efflux measurements in cells expressing mutant NT5C2","journal":"Molecular cancer therapeutics","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (enzymatic assay, metabolomics, transport measurements) in a single study","pmids":["31358663"],"is_preprint":false},{"year":2019,"finding":"NT5C2 mutations alter activating and autoregulatory switch-off mechanisms of the enzyme, resulting in constitutively increased nucleotidase activity; NT5C2 mutant leukemias are chemoresistant to 6-mercaptopurine but show impaired proliferation and self-renewal.","method":"Review synthesizing biochemical, structural, and mouse model data; referenced enzymatic and structural studies","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — synthesis review citing primary mechanistic data, single lab perspective","pmids":["30910786"],"is_preprint":false},{"year":2008,"finding":"Knockdown of NT5C2 (cN-II) in human astrocytoma cells using shRNA reduces enzyme activity and causes apoptosis (increased caspase 3 activity, reduced cell viability) without altering intracellular nucleotide concentrations or energy charge, demonstrating that cN-II activity is essential for cell survival.","method":"shRNA knockdown of NT5C2 in ADF astrocytoma cells, enzymatic activity assay, MTT viability assay, caspase 3 activity measurement, nucleotide concentration measurement","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — clean KD with specific cellular phenotype (apoptosis) and multiple assays, single lab","pmids":["18445485"],"is_preprint":false},{"year":2017,"finding":"Genetic deletion of NT5C2 in mice does not lead to enhanced AMP or ADP concentrations in response to skeletal muscle contraction, and does not potentiate AMPK activation, contradicting prior gene silencing/overexpression studies that suggested NT5C2 controls AMPK via IMP/inosine hydrolysis.","method":"NT5C2 knockout mouse model, electrically stimulated skeletal muscle, intracellular adenine nucleotide level measurement, AMPK activity assay","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knockout with direct biochemical measurements, single lab study","pmids":["28325731"],"is_preprint":false},{"year":2012,"finding":"Virtual screening identified an anthraquinone inhibitor (AdiS) of NT5C2 (cN-II) with a Ki of 2.0 mM; crystallographic soaking experiments at 2.9 Å resolution located AdiS interaction at F354/I152 in effector site 1 of cN-II, and the compound increased apoptosis in cancer cells combined with nucleoside analog drugs.","method":"In silico virtual screening, in vitro enzymatic inhibition assay, X-ray crystallography of truncated cN-II soaked with inhibitor, cell viability assays","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 1 — crystal structure plus in vitro enzymatic assay; single lab, moderate evidence","pmids":["23220537"],"is_preprint":false},{"year":2020,"finding":"Knockdown or knockout of nt5c2 in zebrafish larvae results in significantly higher blood flow, increased arterial pulse, and elevated linear velocity, along with increased expression of hypertension markers (crp and ace), and knockout of nt5c2a reduces expression of cnnm2a, indicating NT5C2 participates in blood pressure regulation.","method":"Morpholino knockdown and CRISPR knockout of nt5c2 in zebrafish larvae, blood flow and arterial pulse measurement, RT-qPCR of hypertension markers","journal":"Frontiers in cardiovascular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — genetic loss-of-function (morpholino and KO) with direct hemodynamic readout and molecular validation","pmids":["32984406"],"is_preprint":false},{"year":2016,"finding":"A schizophrenia protective allele disrupts miR-206 binding to the NT5C2 3'UTR, leading to increased NT5C2 expression, as confirmed by luciferase reporter assay, suggesting post-transcriptional regulation of NT5C2 by miR-206.","method":"Luciferase-based reporter assay testing allele-specific miR-206 binding to NT5C2 3'UTR","journal":"European neuropsychopharmacology","confidence":"Low","confidence_rationale":"Tier 3 — single reporter assay, single lab, no direct functional consequence of altered NT5C2 level established","pmids":["27424800"],"is_preprint":false}],"current_model":"NT5C2 (cytosolic 5'-nucleotidase II/cN-II) is an allosterically regulated enzyme that dephosphorylates purine nucleoside monophosphates (preferentially IMP, GMP, and AMP) to control intracellular nucleotide pools; gain-of-function mutations found in relapsed ALL disrupt either the enzyme's catalytic center geometry or a built-in switch-off mechanism (involving the arm segment, inter-monomeric cavity, and C-terminal acidic tail), rendering the enzyme constitutively active, which accelerates inactivation of thiopurine chemotherapy metabolites and drives 6-mercaptopurine/6-thioguanine resistance at the cost of purine pool depletion and impaired leukemia cell fitness."},"narrative":{"teleology":[{"year":2008,"claim":"Establishing that cN-II activity is required for cell survival resolved whether the enzyme is dispensable or essential in proliferating cells, showing that its loss triggers apoptosis even without measurable changes in bulk nucleotide concentrations.","evidence":"shRNA knockdown in human astrocytoma cells with caspase-3, viability, and nucleotide measurements","pmids":["18445485"],"confidence":"Medium","gaps":["Single cell line; mechanism linking enzyme loss to apoptosis remains unresolved","Bulk nucleotide measurements may miss compartmentalized pool changes"]},{"year":2012,"claim":"Identification of an allosteric inhibitor binding at effector site 1 (F354/I152) provided the first structural view of a druggable regulatory pocket on NT5C2.","evidence":"Virtual screening, enzymatic inhibition assay, and X-ray crystallography of truncated cN-II soaked with anthraquinone inhibitor","pmids":["23220537"],"confidence":"Medium","gaps":["Inhibitor potency is millimolar (Ki 2.0 mM), limiting pharmacological utility","Only a truncated protein was crystallized"]},{"year":2013,"claim":"Two concurrent studies established that relapse-specific activating NT5C2 mutations are a direct genetic cause of thiopurine resistance in ALL, linking enzyme gain-of-function to clinical drug failure.","evidence":"Whole-exome/RNA sequencing of matched diagnosis–relapse ALL samples, in vitro enzymatic assays of mutant proteins, and expression of mutant NT5C2 in ALL lymphoblasts with drug-resistance readout","pmids":["23377281","23377183"],"confidence":"High","gaps":["Structural basis of constitutive activation not yet resolved at this point","Fitness cost of mutations in vivo unknown"]},{"year":2017,"claim":"Genetic knockout of NT5C2 in mice showed the enzyme is dispensable for AMPK activation in contracting skeletal muscle, contradicting earlier knockdown/overexpression data and narrowing the physiological role of NT5C2 away from direct AMPK regulation.","evidence":"NT5C2 knockout mouse, electrically stimulated skeletal muscle contraction, adenine nucleotide and AMPK activity measurements","pmids":["28325731"],"confidence":"Medium","gaps":["Does not rule out tissue-specific roles in other contexts","Compensatory mechanisms in constitutive knockout not addressed"]},{"year":2018,"claim":"Crystal structures of leukemia-associated mutants and biochemical reconstitution of hetero-oligomers revealed two distinct activation mechanisms — catalytic-center reconfiguration (K359Q, L375F) and disruption of the autoinhibitory switch-off (arm segment and inter-monomeric cavity mutations) — and showed that mutant subunits dominantly activate wild-type partners, explaining heterozygous gain-of-function.","evidence":"X-ray crystallography of wild-type and mutant NT5C2, mutagenesis, enzymatic assays, and reconstitution of hetero-oligomeric wild-type/mutant complexes","pmids":["29990496","29535428"],"confidence":"High","gaps":["Full-length wild-type structure in inactive conformation not available","Dynamics of switch-off mechanism not captured by static crystal structures"]},{"year":2018,"claim":"A conditional mouse model demonstrated that constitutive NT5C2 R367Q activity depletes intracellular purine pools via excess purine export, explaining both chemoresistance and the fitness cost (impaired proliferation and self-renewal) of the mutation, and identifying IMPDH inhibition as a therapeutic vulnerability.","evidence":"Conditional-and-inducible NT5C2 R367Q knock-in leukemia mouse model with intracellular nucleotide pool measurements, leukemia-initiating cell assays, and IMPDH inhibitor treatment","pmids":["29342136"],"confidence":"High","gaps":["Clinical validation of IMPDH inhibitor synergy in human patients not established","Whether all mutant alleles produce equivalent purine depletion unknown"]},{"year":2019,"claim":"Detailed metabolomic profiling showed that NT5C2 mutants exhibit neomorphic substrate preference toward thiopurine metabolites over endogenous purines, refining the mechanism of drug resistance beyond simple increased activity.","evidence":"Enzymatic assays comparing substrate specificity of wild-type and mutant NT5C2, intracellular metabolomics, and drug uptake/efflux measurements","pmids":["31358663"],"confidence":"High","gaps":["Structural basis of altered substrate preference not resolved","In vivo metabolomic confirmation in animal models not provided"]},{"year":2020,"claim":"Loss-of-function studies in zebrafish linked NT5C2 to blood pressure regulation, expanding its physiological role beyond purine metabolism in hematopoietic cells.","evidence":"Morpholino knockdown and CRISPR knockout of nt5c2 in zebrafish larvae with hemodynamic and gene expression measurements","pmids":["32984406"],"confidence":"Medium","gaps":["Mechanism connecting nucleotidase activity to vascular tone is unknown","Mammalian validation of cardiovascular phenotype not available","Relationship to GWAS blood pressure loci at NT5C2 locus not functionally demonstrated"]},{"year":null,"claim":"Key unresolved questions include the structural basis of neomorphic substrate preference in mutant NT5C2, the mechanism linking nucleotidase loss to apoptosis, whether IMPDH-based combination therapy is effective against NT5C2-mutant ALL in patients, and how NT5C2 participates in cardiovascular regulation.","evidence":"","pmids":[],"confidence":"High","gaps":["No structure of mutant NT5C2 bound to thiopurine substrate","Molecular pathway from NT5C2 loss to caspase activation uncharacterized","No clinical trial data for IMPDH inhibitor combination in NT5C2-mutant ALL"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,2,3,5]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,1]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,4,5]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1,4,5]}],"complexes":[],"partners":["CNNM2"],"other_free_text":[]},"mechanistic_narrative":"NT5C2 (cytosolic 5'-nucleotidase II, cN-II) is an allosterically regulated phosphohydrolase that dephosphorylates purine nucleoside monophosphates, thereby controlling intracellular purine nucleotide pools and influencing cell survival. The enzyme operates as an oligomer whose activity is governed by allosteric ATP activation, an autoinhibitory switch-off mechanism involving the arm segment, inter-monomeric cavity, and a C-terminal acidic tail, and whose mutant subunits can dominantly activate wild-type partners within hetero-oligomeric complexes [PMID:29990496, PMID:29535428]. Gain-of-function NT5C2 mutations recurrently arise in relapsed acute lymphoblastic leukemia, where constitutive nucleotidase activity accelerates dephosphorylation and export of thiopurine metabolites to confer 6-mercaptopurine/6-thioguanine resistance, while simultaneously depleting intracellular purine pools and impairing leukemia cell proliferation and self-renewal [PMID:23377281, PMID:23377183, PMID:29342136, PMID:31358663]. Loss of NT5C2 in zebrafish increases blood flow and arterial pulse with upregulation of hypertension markers, implicating NT5C2 in blood pressure regulation [PMID:32984406]."},"prefetch_data":{"uniprot":{"accession":"P49902","full_name":"Cytosolic purine 5'-nucleotidase","aliases":["Cytosolic 5'-nucleotidase II","cN-II","Cytosolic IMP/GMP-specific 5'-nucleotidase","Cytosolic nucleoside phosphotransferase 5'N","High Km 5'-nucleotidase"],"length_aa":561,"mass_kda":65.0,"function":"Broad specificity cytosolic 5'-nucleotidase that catalyzes the dephosphorylation of 6-hydroxypurine nucleoside 5'-monophosphates (PubMed:10092873, PubMed:12907246, PubMed:1659319, PubMed:9371705). In addition, possesses a phosphotransferase activity by which it can transfer a phosphate from a donor nucleoside monophosphate to an acceptor nucleoside, preferably inosine, deoxyinosine and guanosine (PubMed:1659319, PubMed:9371705). Has the highest activities for IMP and GMP followed by dIMP, dGMP and XMP (PubMed:10092873, PubMed:12907246, PubMed:1659319, PubMed:9371705). Could also catalyze the transfer of phosphates from pyrimidine monophosphates but with lower efficiency (PubMed:1659319, PubMed:9371705). Through these activities regulates the purine nucleoside/nucleotide pools within the cell (PubMed:10092873, PubMed:12907246, PubMed:1659319, PubMed:9371705)","subcellular_location":"Cytoplasm, cytosol","url":"https://www.uniprot.org/uniprotkb/P49902/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NT5C2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NT5C2","total_profiled":1310},"omim":[{"mim_id":"613162","title":"SPASTIC PARAPLEGIA 45, AUTOSOMAL RECESSIVE; SPG45","url":"https://www.omim.org/entry/613162"},{"mim_id":"613065","title":"LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL","url":"https://www.omim.org/entry/613065"},{"mim_id":"600417","title":"5-PRIME-@NUCLEOTIDASE, CYTOSOLIC II; NT5C2","url":"https://www.omim.org/entry/600417"},{"mim_id":"270800","title":"SPASTIC PARAPLEGIA 5A, AUTOSOMAL RECESSIVE; SPG5A","url":"https://www.omim.org/entry/270800"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/NT5C2"},"hgnc":{"alias_symbol":["PNT5","GMP","cN-II","SPG65"],"prev_symbol":["NT5B","SPG45"]},"alphafold":{"accession":"P49902","domains":[{"cath_id":"3.40.50.1000","chopping":"44-58_226-370","consensus_level":"high","plddt":94.6927,"start":44,"end":370},{"cath_id":"-","chopping":"62-221","consensus_level":"high","plddt":96.4998,"start":62,"end":221}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P49902","model_url":"https://alphafold.ebi.ac.uk/files/AF-P49902-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P49902-F1-predicted_aligned_error_v6.png","plddt_mean":88.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NT5C2","jax_strain_url":"https://www.jax.org/strain/search?query=NT5C2"},"sequence":{"accession":"P49902","fasta_url":"https://rest.uniprot.org/uniprotkb/P49902.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P49902/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P49902"}},"corpus_meta":[{"pmid":"21947006","id":"PMC_21947006","title":"STING is a direct innate immune sensor of cyclic di-GMP.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21947006","citation_count":1291,"is_preprint":false},{"pmid":"10977868","id":"PMC_10977868","title":"Guanylyl cyclases and signaling by cyclic GMP.","date":"2000","source":"Pharmacological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/10977868","citation_count":910,"is_preprint":false},{"pmid":"28163311","id":"PMC_28163311","title":"Cyclic di-GMP: second messenger extraordinaire.","date":"2017","source":"Nature reviews. Microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/28163311","citation_count":751,"is_preprint":false},{"pmid":"26371324","id":"PMC_26371324","title":"Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26371324","citation_count":588,"is_preprint":false},{"pmid":"18635805","id":"PMC_18635805","title":"Riboswitches in eubacteria sense the second messenger cyclic di-GMP.","date":"2008","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18635805","citation_count":534,"is_preprint":false},{"pmid":"7680013","id":"PMC_7680013","title":"Intracellular cyclic GMP receptor proteins.","date":"1993","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/7680013","citation_count":512,"is_preprint":false},{"pmid":"16045609","id":"PMC_16045609","title":"C-di-GMP: the dawning of a novel bacterial signalling system.","date":"2005","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/16045609","citation_count":501,"is_preprint":false},{"pmid":"16895465","id":"PMC_16895465","title":"Mechanisms of cyclic-di-GMP signaling in bacteria.","date":"2006","source":"Annual review of genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16895465","citation_count":492,"is_preprint":false},{"pmid":"31533127","id":"PMC_31533127","title":"Cyclic GMP-AMP signalling protects bacteria against viral infection.","date":"2019","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/31533127","citation_count":440,"is_preprint":false},{"pmid":"15255898","id":"PMC_15255898","title":"Cyclic diguanylate (c-di-GMP) regulates Vibrio cholerae biofilm formation.","date":"2004","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/15255898","citation_count":414,"is_preprint":false},{"pmid":"19756011","id":"PMC_19756011","title":"Structural and mechanistic determinants of c-di-GMP signalling.","date":"2009","source":"Nature reviews. Microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/19756011","citation_count":398,"is_preprint":false},{"pmid":"8156599","id":"PMC_8156599","title":"Cyclic GMP and calcium mediate phytochrome phototransduction.","date":"1994","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8156599","citation_count":330,"is_preprint":false},{"pmid":"19306895","id":"PMC_19306895","title":"Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.","date":"2009","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/19306895","citation_count":326,"is_preprint":false},{"pmid":"23377281","id":"PMC_23377281","title":"Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.","date":"2013","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23377281","citation_count":275,"is_preprint":false},{"pmid":"16923812","id":"PMC_16923812","title":"Allosteric control of cyclic di-GMP signaling.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16923812","citation_count":238,"is_preprint":false},{"pmid":"23377183","id":"PMC_23377183","title":"Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.","date":"2013","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23377183","citation_count":228,"is_preprint":false},{"pmid":"28399655","id":"PMC_28399655","title":"Cyclic GMP-AMP as an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA.","date":"2017","source":"Annual review of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28399655","citation_count":223,"is_preprint":false},{"pmid":"8594612","id":"PMC_8594612","title":"Nitric oxide and cyclic GMP signaling.","date":"1996","source":"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8594612","citation_count":203,"is_preprint":false},{"pmid":"18337116","id":"PMC_18337116","title":"Control of lipolysis by natriuretic peptides and cyclic GMP.","date":"2008","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/18337116","citation_count":186,"is_preprint":false},{"pmid":"17277122","id":"PMC_17277122","title":"Bacterial c-di-GMP is an immunostimulatory molecule.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17277122","citation_count":183,"is_preprint":false},{"pmid":"15289546","id":"PMC_15289546","title":"Cyclic di-GMP as a bacterial second messenger.","date":"2004","source":"Microbiology (Reading, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15289546","citation_count":178,"is_preprint":false},{"pmid":"1693535","id":"PMC_1693535","title":"Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium.","date":"1990","source":"Blood cells","url":"https://pubmed.ncbi.nlm.nih.gov/1693535","citation_count":159,"is_preprint":false},{"pmid":"11433215","id":"PMC_11433215","title":"NO, nitrotyrosine, and cyclic GMP in signal transduction.","date":"2001","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/11433215","citation_count":158,"is_preprint":false},{"pmid":"2873213","id":"PMC_2873213","title":"Cyclic GMP as mediator and biological marker of atrial natriuretic factor.","date":"1986","source":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/2873213","citation_count":156,"is_preprint":false},{"pmid":"12791979","id":"PMC_12791979","title":"Wnt signaling, Ca2+, and cyclic GMP: visualizing Frizzled functions.","date":"2003","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12791979","citation_count":115,"is_preprint":false},{"pmid":"21320509","id":"PMC_21320509","title":"Cyclic di-GMP activation of polynucleotide phosphorylase signal-dependent RNA processing.","date":"2011","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21320509","citation_count":111,"is_preprint":false},{"pmid":"10395405","id":"PMC_10395405","title":"Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology.","date":"1999","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/10395405","citation_count":105,"is_preprint":false},{"pmid":"29342136","id":"PMC_29342136","title":"Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29342136","citation_count":99,"is_preprint":false},{"pmid":"15769622","id":"PMC_15769622","title":"Role of cyclic GMP in gene regulation.","date":"2005","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/15769622","citation_count":98,"is_preprint":false},{"pmid":"2901694","id":"PMC_2901694","title":"Cyclic GMP and cell death in rat cerebellar slices.","date":"1988","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/2901694","citation_count":95,"is_preprint":false},{"pmid":"22821967","id":"PMC_22821967","title":"Evidence for cyclic Di-GMP-mediated signaling in Bacillus subtilis.","date":"2012","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/22821967","citation_count":92,"is_preprint":false},{"pmid":"15635450","id":"PMC_15635450","title":"Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease.","date":"2005","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15635450","citation_count":89,"is_preprint":false},{"pmid":"15312981","id":"PMC_15312981","title":"Cyclic GMP transporters.","date":"2004","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/15312981","citation_count":85,"is_preprint":false},{"pmid":"2879892","id":"PMC_2879892","title":"Phosphorylation of tyrosine hydroxylase by cyclic GMP-dependent protein kinase.","date":"1987","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2879892","citation_count":83,"is_preprint":false},{"pmid":"28990312","id":"PMC_28990312","title":"Cyclic-di-GMP regulation of virulence in bacterial pathogens.","date":"2017","source":"Wiley interdisciplinary reviews. RNA","url":"https://pubmed.ncbi.nlm.nih.gov/28990312","citation_count":82,"is_preprint":false},{"pmid":"15229623","id":"PMC_15229623","title":"Nitric oxide-cyclic GMP pathway with some emphasis on cavernosal contractility.","date":"2004","source":"International journal of impotence research","url":"https://pubmed.ncbi.nlm.nih.gov/15229623","citation_count":76,"is_preprint":false},{"pmid":"29550520","id":"PMC_29550520","title":"Nitric oxide and cyclic GMP functions in bone.","date":"2018","source":"Nitric oxide : biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29550520","citation_count":70,"is_preprint":false},{"pmid":"6327179","id":"PMC_6327179","title":"Transducin and the cyclic GMP phosphodiesterase: amplifier proteins in vision.","date":"1983","source":"Cold Spring Harbor symposia on quantitative biology","url":"https://pubmed.ncbi.nlm.nih.gov/6327179","citation_count":69,"is_preprint":false},{"pmid":"171310","id":"PMC_171310","title":"Cyclic GMP and lectin-induced lymphocyte activation.","date":"1975","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/171310","citation_count":64,"is_preprint":false},{"pmid":"10662722","id":"PMC_10662722","title":"Guanylin peptides: renal actions mediated by cyclic GMP.","date":"2000","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10662722","citation_count":60,"is_preprint":false},{"pmid":"8038108","id":"PMC_8038108","title":"Cyclic GMP and regulation of cyclic nucleotide hydrolysis.","date":"1994","source":"Advances in pharmacology (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/8038108","citation_count":57,"is_preprint":false},{"pmid":"19494585","id":"PMC_19494585","title":"Prevailing concepts of c-di-GMP signaling.","date":"2009","source":"Contributions to microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/19494585","citation_count":56,"is_preprint":false},{"pmid":"35479330","id":"PMC_35479330","title":"Cyclic GMP and PKG Signaling in Heart Failure.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35479330","citation_count":56,"is_preprint":false},{"pmid":"10608283","id":"PMC_10608283","title":"Role of cyclic GMP in glutamate neurotoxicity in primary cultures of cerebellar neurons.","date":"1999","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10608283","citation_count":55,"is_preprint":false},{"pmid":"32176702","id":"PMC_32176702","title":"Reciprocal c-di-GMP signaling: Incomplete flagellum biogenesis triggers c-di-GMP signaling pathways that promote biofilm formation.","date":"2020","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32176702","citation_count":54,"is_preprint":false},{"pmid":"18310115","id":"PMC_18310115","title":"A new role for a classical gene: white transports cyclic GMP.","date":"2008","source":"The Journal of experimental biology","url":"https://pubmed.ncbi.nlm.nih.gov/18310115","citation_count":53,"is_preprint":false},{"pmid":"29909913","id":"PMC_29909913","title":"GMP CAR-T cell production.","date":"2018","source":"Best practice & research. Clinical haematology","url":"https://pubmed.ncbi.nlm.nih.gov/29909913","citation_count":50,"is_preprint":false},{"pmid":"29383123","id":"PMC_29383123","title":"Circular RNA circ-NT5C2 acts as an oncogene in osteosarcoma proliferation and metastasis through targeting miR-448.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29383123","citation_count":49,"is_preprint":false},{"pmid":"1697545","id":"PMC_1697545","title":"Cyclic GMP and photoreceptor function.","date":"1990","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/1697545","citation_count":49,"is_preprint":false},{"pmid":"2890172","id":"PMC_2890172","title":"Regulation and role of guanylate cyclase-cyclic GMP in vascular relaxation.","date":"1987","source":"Progress in clinical and biological research","url":"https://pubmed.ncbi.nlm.nih.gov/2890172","citation_count":47,"is_preprint":false},{"pmid":"19327118","id":"PMC_19327118","title":"Regulation of c-di-GMP metabolism in biofilms.","date":"2009","source":"Future microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/19327118","citation_count":46,"is_preprint":false},{"pmid":"34163453","id":"PMC_34163453","title":"OpaR Controls the Metabolism of c-di-GMP in Vibrio parahaemolyticus.","date":"2021","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/34163453","citation_count":45,"is_preprint":false},{"pmid":"22875455","id":"PMC_22875455","title":"Phosphodiesterases and cyclic GMP regulation in heart muscle.","date":"2012","source":"Physiology (Bethesda, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/22875455","citation_count":43,"is_preprint":false},{"pmid":"2832200","id":"PMC_2832200","title":"Cyclic GMP-phosphodiesterase of rd retina: biosynthesis and content.","date":"1988","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/2832200","citation_count":43,"is_preprint":false},{"pmid":"29990496","id":"PMC_29990496","title":"Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.","date":"2018","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/29990496","citation_count":42,"is_preprint":false},{"pmid":"10845107","id":"PMC_10845107","title":"Mechanisms of guanylin action via cyclic GMP in the kidney.","date":"2000","source":"Annual review of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10845107","citation_count":42,"is_preprint":false},{"pmid":"23881098","id":"PMC_23881098","title":"A cyclic GMP-dependent signalling pathway regulates bacterial phytopathogenesis.","date":"2013","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/23881098","citation_count":42,"is_preprint":false},{"pmid":"32540968","id":"PMC_32540968","title":"Dysfunctional telomeres trigger cellular senescence mediated by cyclic GMP-AMP synthase.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32540968","citation_count":42,"is_preprint":false},{"pmid":"18445485","id":"PMC_18445485","title":"Knockdown of cytosolic 5'-nucleotidase II (cN-II) reveals that its activity is essential for survival in astrocytoma cells.","date":"2008","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/18445485","citation_count":42,"is_preprint":false},{"pmid":"29967320","id":"PMC_29967320","title":"BrlR from Pseudomonas aeruginosa is a receptor for both cyclic di-GMP and pyocyanin.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29967320","citation_count":41,"is_preprint":false},{"pmid":"30910786","id":"PMC_30910786","title":"Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/30910786","citation_count":40,"is_preprint":false},{"pmid":"27004590","id":"PMC_27004590","title":"Genome-wide significant schizophrenia risk variation on chromosome 10q24 is associated with altered cis-regulation of BORCS7, AS3MT, and NT5C2 in the human brain.","date":"2016","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27004590","citation_count":40,"is_preprint":false},{"pmid":"7706277","id":"PMC_7706277","title":"Biochemical characterization of human GMP synthetase.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7706277","citation_count":40,"is_preprint":false},{"pmid":"21098727","id":"PMC_21098727","title":"Cyclic-di-GMP reaches out into the bacterial RNA world.","date":"2010","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/21098727","citation_count":35,"is_preprint":false},{"pmid":"24444305","id":"PMC_24444305","title":"Serum and supplement optimization for EU GMP-compliance in cardiospheres cell culture.","date":"2014","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24444305","citation_count":34,"is_preprint":false},{"pmid":"27079836","id":"PMC_27079836","title":"Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension.","date":"2016","source":"Current hypertension reports","url":"https://pubmed.ncbi.nlm.nih.gov/27079836","citation_count":32,"is_preprint":false},{"pmid":"6313433","id":"PMC_6313433","title":"Cyclic GMP-dependent protein phosphorylation in mammalian brain.","date":"1983","source":"Federation proceedings","url":"https://pubmed.ncbi.nlm.nih.gov/6313433","citation_count":32,"is_preprint":false},{"pmid":"9352612","id":"PMC_9352612","title":"Models of persistent pulmonary hypertension of the newborn (PPHN) and the role of cyclic guanosine monophosphate (GMP) in pulmonary vasorelaxation.","date":"1997","source":"Seminars in perinatology","url":"https://pubmed.ncbi.nlm.nih.gov/9352612","citation_count":31,"is_preprint":false},{"pmid":"20195723","id":"PMC_20195723","title":"Cyclic GMP pathways in hepatic encephalopathy. Neurological and therapeutic implications.","date":"2010","source":"Metabolic brain disease","url":"https://pubmed.ncbi.nlm.nih.gov/20195723","citation_count":31,"is_preprint":false},{"pmid":"10545631","id":"PMC_10545631","title":"Cyclic GMP and outer hair cell electromotility.","date":"1999","source":"Hearing research","url":"https://pubmed.ncbi.nlm.nih.gov/10545631","citation_count":30,"is_preprint":false},{"pmid":"28320886","id":"PMC_28320886","title":"Optogenetic Module for Dichromatic Control of c-di-GMP Signaling.","date":"2017","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/28320886","citation_count":29,"is_preprint":false},{"pmid":"37980414","id":"PMC_37980414","title":"c-di-GMP inhibits the DNA binding activity of H-NS in Salmonella.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37980414","citation_count":28,"is_preprint":false},{"pmid":"15670873","id":"PMC_15670873","title":"Cyclic GMP signaling and regulation of SERCA activity during cardiac myocyte contraction.","date":"2005","source":"Cell calcium","url":"https://pubmed.ncbi.nlm.nih.gov/15670873","citation_count":28,"is_preprint":false},{"pmid":"24591051","id":"PMC_24591051","title":"Cyclic GMP is involved in auxin signalling during Arabidopsis root growth and development.","date":"2014","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/24591051","citation_count":28,"is_preprint":false},{"pmid":"2166585","id":"PMC_2166585","title":"Cyclic GMP-activated protein kinase from Dictyostelium discoideum.","date":"1990","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/2166585","citation_count":27,"is_preprint":false},{"pmid":"28325731","id":"PMC_28325731","title":"Effects of genetic deletion of soluble 5'-nucleotidases NT5C1A and NT5C2 on AMPK activation and nucleotide levels in contracting mouse skeletal muscles.","date":"2017","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28325731","citation_count":26,"is_preprint":false},{"pmid":"29535428","id":"PMC_29535428","title":"Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation.","date":"2018","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/29535428","citation_count":26,"is_preprint":false},{"pmid":"23220537","id":"PMC_23220537","title":"Identification and characterization of inhibitors of cytoplasmic 5'-nucleotidase cN-II issued from virtual screening.","date":"2012","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23220537","citation_count":26,"is_preprint":false},{"pmid":"23992314","id":"PMC_23992314","title":"Therapeutic perspectives for cN-II in cancer.","date":"2013","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23992314","citation_count":26,"is_preprint":false},{"pmid":"29982829","id":"PMC_29982829","title":"Cyclic di-GMP integrates functionally divergent transcription factors into a regulation pathway for antioxidant defense.","date":"2018","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/29982829","citation_count":26,"is_preprint":false},{"pmid":"23256840","id":"PMC_23256840","title":"Identification of c-di-GMP derivatives resistant to an EAL domain phosphodiesterase.","date":"2013","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23256840","citation_count":24,"is_preprint":false},{"pmid":"16139477","id":"PMC_16139477","title":"A role for cyclic-GMP dependent protein kinase in anoikis.","date":"2005","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/16139477","citation_count":23,"is_preprint":false},{"pmid":"27424800","id":"PMC_27424800","title":"Schizophrenia risk variants affecting microRNA function and site-specific regulation of NT5C2 by miR-206.","date":"2016","source":"European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27424800","citation_count":23,"is_preprint":false},{"pmid":"23223233","id":"PMC_23223233","title":"Identification of Drosophila and human 7-methyl GMP-specific nucleotidases.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23223233","citation_count":23,"is_preprint":false},{"pmid":"16288457","id":"PMC_16288457","title":"Unique GMP-binding site in Mycobacterium tuberculosis guanosine monophosphate kinase.","date":"2006","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/16288457","citation_count":22,"is_preprint":false},{"pmid":"12940543","id":"PMC_12940543","title":"Towards the ideal GMP: homologous recombination and marker gene excision.","date":"2003","source":"Journal of plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12940543","citation_count":21,"is_preprint":false},{"pmid":"32589664","id":"PMC_32589664","title":"c-di-GMP inhibits LonA-dependent proteolysis of TfoY in Vibrio cholerae.","date":"2020","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32589664","citation_count":21,"is_preprint":false},{"pmid":"12095656","id":"PMC_12095656","title":"Cyclic guanosine 5' monophosphate (GMP) prevents expression of neuronal nitric oxide synthase and apoptosis in motor neurons deprived of trophic factors in rats.","date":"2002","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/12095656","citation_count":21,"is_preprint":false},{"pmid":"20978093","id":"PMC_20978093","title":"Cyclic GMP kinase I modulates glucagon release from pancreatic α-cells.","date":"2010","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/20978093","citation_count":21,"is_preprint":false},{"pmid":"35963468","id":"PMC_35963468","title":"Design and manufacture of a lyophilised faecal microbiota capsule formulation to GMP standards.","date":"2022","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/35963468","citation_count":21,"is_preprint":false},{"pmid":"31358663","id":"PMC_31358663","title":"Mechanisms of NT5C2-Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia.","date":"2019","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/31358663","citation_count":20,"is_preprint":false},{"pmid":"34878288","id":"PMC_34878288","title":"c-di-GMP Inhibits Early Sporulation in Clostridioides difficile.","date":"2021","source":"mSphere","url":"https://pubmed.ncbi.nlm.nih.gov/34878288","citation_count":19,"is_preprint":false},{"pmid":"32984406","id":"PMC_32984406","title":"Studies in Zebrafish Demonstrate That CNNM2 and NT5C2 Are Most Likely the Causal Genes at the Blood Pressure-Associated Locus on Human Chromosome 10q24.32.","date":"2020","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32984406","citation_count":19,"is_preprint":false},{"pmid":"31576744","id":"PMC_31576744","title":"NosP Modulates Cyclic-di-GMP Signaling in Legionella pneumophila.","date":"2019","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31576744","citation_count":19,"is_preprint":false},{"pmid":"2886220","id":"PMC_2886220","title":"Mechanism of vasodilation by nitrates: role of cyclic GMP.","date":"1987","source":"Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/2886220","citation_count":19,"is_preprint":false},{"pmid":"29610212","id":"PMC_29610212","title":"Cyclic di-GMP Positively Regulates DNA Repair in Vibrio cholerae.","date":"2018","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/29610212","citation_count":18,"is_preprint":false},{"pmid":"8112582","id":"PMC_8112582","title":"Cloning and sequencing of the GMP synthetase-encoding gene of Saccharomyces cerevisiae.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8112582","citation_count":18,"is_preprint":false},{"pmid":"30362044","id":"PMC_30362044","title":"Expanding the clinical relevance of the 5'-nucleotidase cN-II/NT5C2.","date":"2018","source":"Purinergic signalling","url":"https://pubmed.ncbi.nlm.nih.gov/30362044","citation_count":17,"is_preprint":false},{"pmid":"32045871","id":"PMC_32045871","title":"Legionella quorum sensing meets cyclic-di-GMP signaling.","date":"2020","source":"Current opinion in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/32045871","citation_count":17,"is_preprint":false},{"pmid":"18775979","id":"PMC_18775979","title":"Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53.","date":"2008","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/18775979","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43074,"output_tokens":2938,"usd":0.086646},"stage2":{"model":"claude-opus-4-6","input_tokens":6285,"output_tokens":2202,"usd":0.129713},"total_usd":0.216359,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"Activating mutations in NT5C2 (cytosolic 5'-nucleotidase II) confer increased nucleotidase activity in vitro and drive resistance to 6-mercaptopurine and 6-thioguanine chemotherapy when expressed in ALL lymphoblasts, identifying NT5C2 as the enzyme responsible for inactivation of nucleoside-analog chemotherapy drugs.\",\n      \"method\": \"Whole-exome sequencing of relapsed ALL samples, in vitro enzymatic activity assays of mutant proteins, expression of mutant NT5C2 in ALL lymphoblasts with chemotherapy resistance readout\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro enzymatic assay plus functional cell-based resistance assay, independently replicated in concurrent paper (PMID:23377183)\",\n      \"pmids\": [\"23377281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Relapse-specific NT5C2 base substitution mutations confer increased enzymatic (5'-nucleotidase) activity and resistance to nucleoside analog therapies; all affected individuals harboring NT5C2 mutations relapsed early (within 36 months), consistent with outgrowth of drug-resistant clones.\",\n      \"method\": \"RNA sequencing of matched diagnosis/relapse bone marrow, full-exon sequencing of NT5C2, enzymatic analysis of mutant proteins showing increased activity\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — enzymatic characterization of mutant proteins, replicated across independent cohort\",\n      \"pmids\": [\"23377183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Crystal structures of NT5C2 mutants K359Q and L375F reveal they reconfigure the catalytic center for substrate access and catalysis in the absence of allosteric activator; most relapse-associated mutations in the arm segment and inter-monomeric cavity disrupt a built-in switch-off mechanism; the C-terminal acidic tail (lost in Q523X) functions to restrain NT5C2 activation.\",\n      \"method\": \"X-ray crystallography of wild-type and mutant NT5C2 proteins, functional enzymatic assays, mutagenesis\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures combined with functional mutagenesis and enzymatic assays in a single rigorous study\",\n      \"pmids\": [\"29990496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"All leukemia-associated NT5C2 mutants are constitutively active independent of allosteric ATP effects; 90% of leukemia-specific alleles directly affect two regulatory hotspots (helix A region residues 355-365, and intersubunit interface helix B 232-242 and flexible loop L 400-418); activation is transmitted from mutant to wild-type subunits in hetero-oligomeric complexes, explaining dominant activity from heterozygous mutations.\",\n      \"method\": \"Structural mapping of mutations, biochemical characterization of hetero-oligomeric complexes combining wild-type and mutant subunits, enzymatic activity assays\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — structural mapping plus biochemical reconstitution of hetero-oligomers with functional readout\",\n      \"pmids\": [\"29535428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Expression of NT5C2 R367Q mutation induces resistance to 6-mercaptopurine at the cost of impaired leukemia cell growth and leukaemia-initiating cell activity due to excess export of purines to the extracellular space and depletion of the intracellular purine-nucleotide pool; inhibition of IMPDH increased cytotoxicity against NT5C2-mutant lymphoblasts.\",\n      \"method\": \"Conditional-and-inducible leukaemia mouse model expressing NT5C2 R367Q, intracellular purine nucleotide pool measurements, IMPDH inhibition experiments\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo conditional model with multiple orthogonal mechanistic readouts (nucleotide pool, cell growth, self-renewal, drug sensitivity)\",\n      \"pmids\": [\"29342136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NT5C2 mutant proteins show elevated 5'-nucleotidase activity with preferential activity toward thiopurine metabolites over endogenous purine nucleotides (neomorphic substrate preference); mutant NT5C2 expression reduces thiopurine uptake and increases efflux of 6-MP metabolites, and causes global shifts in intracellular nucleotide homeostasis.\",\n      \"method\": \"Biochemical enzymatic assays with mutant vs. wild-type NT5C2, intracellular metabolomic profiling, drug uptake and efflux measurements in cells expressing mutant NT5C2\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (enzymatic assay, metabolomics, transport measurements) in a single study\",\n      \"pmids\": [\"31358663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NT5C2 mutations alter activating and autoregulatory switch-off mechanisms of the enzyme, resulting in constitutively increased nucleotidase activity; NT5C2 mutant leukemias are chemoresistant to 6-mercaptopurine but show impaired proliferation and self-renewal.\",\n      \"method\": \"Review synthesizing biochemical, structural, and mouse model data; referenced enzymatic and structural studies\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — synthesis review citing primary mechanistic data, single lab perspective\",\n      \"pmids\": [\"30910786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Knockdown of NT5C2 (cN-II) in human astrocytoma cells using shRNA reduces enzyme activity and causes apoptosis (increased caspase 3 activity, reduced cell viability) without altering intracellular nucleotide concentrations or energy charge, demonstrating that cN-II activity is essential for cell survival.\",\n      \"method\": \"shRNA knockdown of NT5C2 in ADF astrocytoma cells, enzymatic activity assay, MTT viability assay, caspase 3 activity measurement, nucleotide concentration measurement\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KD with specific cellular phenotype (apoptosis) and multiple assays, single lab\",\n      \"pmids\": [\"18445485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Genetic deletion of NT5C2 in mice does not lead to enhanced AMP or ADP concentrations in response to skeletal muscle contraction, and does not potentiate AMPK activation, contradicting prior gene silencing/overexpression studies that suggested NT5C2 controls AMPK via IMP/inosine hydrolysis.\",\n      \"method\": \"NT5C2 knockout mouse model, electrically stimulated skeletal muscle, intracellular adenine nucleotide level measurement, AMPK activity assay\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with direct biochemical measurements, single lab study\",\n      \"pmids\": [\"28325731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Virtual screening identified an anthraquinone inhibitor (AdiS) of NT5C2 (cN-II) with a Ki of 2.0 mM; crystallographic soaking experiments at 2.9 Å resolution located AdiS interaction at F354/I152 in effector site 1 of cN-II, and the compound increased apoptosis in cancer cells combined with nucleoside analog drugs.\",\n      \"method\": \"In silico virtual screening, in vitro enzymatic inhibition assay, X-ray crystallography of truncated cN-II soaked with inhibitor, cell viability assays\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus in vitro enzymatic assay; single lab, moderate evidence\",\n      \"pmids\": [\"23220537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Knockdown or knockout of nt5c2 in zebrafish larvae results in significantly higher blood flow, increased arterial pulse, and elevated linear velocity, along with increased expression of hypertension markers (crp and ace), and knockout of nt5c2a reduces expression of cnnm2a, indicating NT5C2 participates in blood pressure regulation.\",\n      \"method\": \"Morpholino knockdown and CRISPR knockout of nt5c2 in zebrafish larvae, blood flow and arterial pulse measurement, RT-qPCR of hypertension markers\",\n      \"journal\": \"Frontiers in cardiovascular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function (morpholino and KO) with direct hemodynamic readout and molecular validation\",\n      \"pmids\": [\"32984406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A schizophrenia protective allele disrupts miR-206 binding to the NT5C2 3'UTR, leading to increased NT5C2 expression, as confirmed by luciferase reporter assay, suggesting post-transcriptional regulation of NT5C2 by miR-206.\",\n      \"method\": \"Luciferase-based reporter assay testing allele-specific miR-206 binding to NT5C2 3'UTR\",\n      \"journal\": \"European neuropsychopharmacology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single reporter assay, single lab, no direct functional consequence of altered NT5C2 level established\",\n      \"pmids\": [\"27424800\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NT5C2 (cytosolic 5'-nucleotidase II/cN-II) is an allosterically regulated enzyme that dephosphorylates purine nucleoside monophosphates (preferentially IMP, GMP, and AMP) to control intracellular nucleotide pools; gain-of-function mutations found in relapsed ALL disrupt either the enzyme's catalytic center geometry or a built-in switch-off mechanism (involving the arm segment, inter-monomeric cavity, and C-terminal acidic tail), rendering the enzyme constitutively active, which accelerates inactivation of thiopurine chemotherapy metabolites and drives 6-mercaptopurine/6-thioguanine resistance at the cost of purine pool depletion and impaired leukemia cell fitness.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"NT5C2 (cytosolic 5'-nucleotidase II, cN-II) is an allosterically regulated phosphohydrolase that dephosphorylates purine nucleoside monophosphates, thereby controlling intracellular purine nucleotide pools and influencing cell survival. The enzyme operates as an oligomer whose activity is governed by allosteric ATP activation, an autoinhibitory switch-off mechanism involving the arm segment, inter-monomeric cavity, and a C-terminal acidic tail, and whose mutant subunits can dominantly activate wild-type partners within hetero-oligomeric complexes [PMID:29990496, PMID:29535428]. Gain-of-function NT5C2 mutations recurrently arise in relapsed acute lymphoblastic leukemia, where constitutive nucleotidase activity accelerates dephosphorylation and export of thiopurine metabolites to confer 6-mercaptopurine/6-thioguanine resistance, while simultaneously depleting intracellular purine pools and impairing leukemia cell proliferation and self-renewal [PMID:23377281, PMID:23377183, PMID:29342136, PMID:31358663]. Loss of NT5C2 in zebrafish increases blood flow and arterial pulse with upregulation of hypertension markers, implicating NT5C2 in blood pressure regulation [PMID:32984406].\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Establishing that cN-II activity is required for cell survival resolved whether the enzyme is dispensable or essential in proliferating cells, showing that its loss triggers apoptosis even without measurable changes in bulk nucleotide concentrations.\",\n      \"evidence\": \"shRNA knockdown in human astrocytoma cells with caspase-3, viability, and nucleotide measurements\",\n      \"pmids\": [\"18445485\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell line; mechanism linking enzyme loss to apoptosis remains unresolved\", \"Bulk nucleotide measurements may miss compartmentalized pool changes\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identification of an allosteric inhibitor binding at effector site 1 (F354/I152) provided the first structural view of a druggable regulatory pocket on NT5C2.\",\n      \"evidence\": \"Virtual screening, enzymatic inhibition assay, and X-ray crystallography of truncated cN-II soaked with anthraquinone inhibitor\",\n      \"pmids\": [\"23220537\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Inhibitor potency is millimolar (Ki 2.0 mM), limiting pharmacological utility\", \"Only a truncated protein was crystallized\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Two concurrent studies established that relapse-specific activating NT5C2 mutations are a direct genetic cause of thiopurine resistance in ALL, linking enzyme gain-of-function to clinical drug failure.\",\n      \"evidence\": \"Whole-exome/RNA sequencing of matched diagnosis–relapse ALL samples, in vitro enzymatic assays of mutant proteins, and expression of mutant NT5C2 in ALL lymphoblasts with drug-resistance readout\",\n      \"pmids\": [\"23377281\", \"23377183\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of constitutive activation not yet resolved at this point\", \"Fitness cost of mutations in vivo unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Genetic knockout of NT5C2 in mice showed the enzyme is dispensable for AMPK activation in contracting skeletal muscle, contradicting earlier knockdown/overexpression data and narrowing the physiological role of NT5C2 away from direct AMPK regulation.\",\n      \"evidence\": \"NT5C2 knockout mouse, electrically stimulated skeletal muscle contraction, adenine nucleotide and AMPK activity measurements\",\n      \"pmids\": [\"28325731\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not rule out tissue-specific roles in other contexts\", \"Compensatory mechanisms in constitutive knockout not addressed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Crystal structures of leukemia-associated mutants and biochemical reconstitution of hetero-oligomers revealed two distinct activation mechanisms — catalytic-center reconfiguration (K359Q, L375F) and disruption of the autoinhibitory switch-off (arm segment and inter-monomeric cavity mutations) — and showed that mutant subunits dominantly activate wild-type partners, explaining heterozygous gain-of-function.\",\n      \"evidence\": \"X-ray crystallography of wild-type and mutant NT5C2, mutagenesis, enzymatic assays, and reconstitution of hetero-oligomeric wild-type/mutant complexes\",\n      \"pmids\": [\"29990496\", \"29535428\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length wild-type structure in inactive conformation not available\", \"Dynamics of switch-off mechanism not captured by static crystal structures\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"A conditional mouse model demonstrated that constitutive NT5C2 R367Q activity depletes intracellular purine pools via excess purine export, explaining both chemoresistance and the fitness cost (impaired proliferation and self-renewal) of the mutation, and identifying IMPDH inhibition as a therapeutic vulnerability.\",\n      \"evidence\": \"Conditional-and-inducible NT5C2 R367Q knock-in leukemia mouse model with intracellular nucleotide pool measurements, leukemia-initiating cell assays, and IMPDH inhibitor treatment\",\n      \"pmids\": [\"29342136\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Clinical validation of IMPDH inhibitor synergy in human patients not established\", \"Whether all mutant alleles produce equivalent purine depletion unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Detailed metabolomic profiling showed that NT5C2 mutants exhibit neomorphic substrate preference toward thiopurine metabolites over endogenous purines, refining the mechanism of drug resistance beyond simple increased activity.\",\n      \"evidence\": \"Enzymatic assays comparing substrate specificity of wild-type and mutant NT5C2, intracellular metabolomics, and drug uptake/efflux measurements\",\n      \"pmids\": [\"31358663\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of altered substrate preference not resolved\", \"In vivo metabolomic confirmation in animal models not provided\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Loss-of-function studies in zebrafish linked NT5C2 to blood pressure regulation, expanding its physiological role beyond purine metabolism in hematopoietic cells.\",\n      \"evidence\": \"Morpholino knockdown and CRISPR knockout of nt5c2 in zebrafish larvae with hemodynamic and gene expression measurements\",\n      \"pmids\": [\"32984406\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism connecting nucleotidase activity to vascular tone is unknown\", \"Mammalian validation of cardiovascular phenotype not available\", \"Relationship to GWAS blood pressure loci at NT5C2 locus not functionally demonstrated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of neomorphic substrate preference in mutant NT5C2, the mechanism linking nucleotidase loss to apoptosis, whether IMPDH-based combination therapy is effective against NT5C2-mutant ALL in patients, and how NT5C2 participates in cardiovascular regulation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of mutant NT5C2 bound to thiopurine substrate\", \"Molecular pathway from NT5C2 loss to caspase activation uncharacterized\", \"No clinical trial data for IMPDH inhibitor combination in NT5C2-mutant ALL\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 2, 3, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 4, 5]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 4, 5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CNNM2\"],\n    \"other_free_text\": []\n  }\n}\n```"}